Lowest Price Guaranteed From USD 5,499
Published
March 2021
Pages
315
View Count
6500
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Given their ability to treat a wide range of clinical conditions, including oncological disorders, cardiovascular disorders, genetic disorders, ophthalmic diseases and orthopedic disorders, advanced therapy medicinal products (ATMPs) have revolutionized the delivery of healthcare. Presently, over 30 cell and gene therapies have received marketing approval, while around 1,000 therapeutic leads are under evaluation. Considering the advantages of ATMPs, and their ability to address the underlying causes of several serious clinical conditions wherein small molecule drugs have been proven to be inadequate, the preference for such therapeutic modalities is on the rise. In fact, experts believe that, by 2030, 40 - 60 such products are likely to be approved in the US alone. However, as is the case for all biological products, the development of cell and gene therapies is both complex and challenging, as well as subject to heavy regulatory scrutiny. Outsourcing is, therefore, a preferred operational model in this field, with innovator companies relying heavily on specialty contract service providers to handle various aspects of their product development and manufacturing operations.
Contract research organizations (CROs) that claim to have the necessary capabilities to facilitate cell and gene therapy-related R&D, usually have extensive experience and are well-aware of the nuances of ATMP design and development. Moreover, innovators that rely on the aforementioned CROs end up saving significant capital, which would otherwise have been spent on developing R&D infrastructure and / or expertise. Overall, engaging the services of an experienced CRO for cell and gene therapy-related R&D offers certain time-related advantages, as well, to sponsors. Over the years, several contract service providers have also formed strategic alliances and consolidated their positions in the market, by upgrading / expanding existing capabilities and collaborating with other stakeholders in order to expand their service portfolios or geographical reach. Further, CROs have made significant investments towards the development / adoption of advanced tools, technologies and platforms, in order to generate more robust and evidence based clinical data, which is required for gaining the marketing authorizations across different geographies. Given the rising trend of outsourcing in the healthcare industry and the ongoing efforts of service providers to further improve / expand their respective offerings, we believe the cell and gene therapy CRO market is likely to evolve at a steady pace, till 2030.
The “Cell and Gene Therapy CROs Market (2nd Edition), 2021-2030: Distribution by Type of Therapy (Cell Therapy and Gene Therapy), Scale of Operation (Clinical and Preclinical), Therapeutic Area (Oncological Disorders, Cardiovascular Disorders, Inflammatory Disorders, Neurological Disorders, and Other Therapeutic Areas), and Geography (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World)” report features an extensive study of the current market landscape and the likely future potential of the cell and gene therapy CROs market, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. Amongst other elements, the report features:
One of the key objectives of this report was to evaluate the current opportunity and the future potential of the cell and gene therapy CROs market over the coming decade. We have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2021-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] type of therapy (cell therapy and gene therapy), [B] scale of operation (clinical and preclinical), [C] target therapeutic area (oncology and non-oncology) and [D] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA (Middle East and North Africa) and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
The opinions and insights presented in this study were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry and non-industry players:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the current state of cell and gene therapy CROs market and its likely evolution in the mid-long term.
Chapter 3 provides a general introduction to CROs, featuring insights on the historical evolution of such organizations, legacy and contemporary trends in outsourcing activity. It provides a brief introduction to the concept of CROs, featuring a discussion on the historical evolution of contract research services market in this domain. Additionally, it includes details on the various types of services offered by different CROs. Further, the chapter highlights advantages and risks associated in partnering with contract service providers, and their role in the development of ATMPs.
Chapter 4 provides a detailed discussion on the business models that are commonly adopted by the biopharmaceutical industry for outsourcing cell and gene therapies. In addition, it includes information on various factors that drive sponsors towards outsourcing and key parameters that sponsors must consider while choosing CROs at each phase of drug development process.
Chapter 5 provides a detailed review of the overall landscape of the cell and gene therapy services market, highlighting the contributions of CROs, along with the information on year of establishment, company size, location of headquarters, A detailed assessment of the overall market landscape of about 100 CROs offering cell and gene therapies based on a number of relevant parameters, such as type of therapy (cell therapy (stem cells, T cells, dendritic cells, NK cells and tumor cells) and gene therapy), scale of operation (clinical and preclinical) and types of services offered including [A] clinical services (clinical trial management, clinical trial monitoring, data management and project management, clinical safety and quality studies, regulatory services, consultancy services and IT / informatics services) and [B] preclinical services (bioanalytical services, toxicology studies, in vivo studies, preclinical safety and quality studies and support services).
Chapter 6 features elaborate profiles of prominent CROs engaged in offering cell and gene therapy related services. Each company profile features a brief overview of the company, along with information on year of establishment, number of employees, location of headquarters, key executives, financial details / information (if available), service portfolio, recent developments and an informed future outlook.
Chapter 7 presents a benchmark analysis of the various players engaged in this domain. It highlights the capabilities of the companies (in terms of their expertise across various services related to the development of cell and gene therapies). The analysis allows companies to compare their existing capabilities within and beyond their peer groups and identify opportunities to become more competitive in the industry.
Chapter 8 features an analysis of the various partnerships inked between CROs offering cell and gene therapy related services, which have been established during the period 2015-2020. It includes a brief description of various types of partnerships models (such as outsourcing agreements, licensing agreements, and service alliances) that have been adopted by stakeholders engaged in this domain since 2015.
Chapter 9 presents insights from a detailed analysis of the various mergers and acquisitions that have taken place in this domain, during the period 2015-2020. It is worth mentioning that the data captured during our research was analyzed based on several parameters, such as year, type of acquisition, geographical location of the companies, type of therapy and type of cells.
Chapter 10 provides a detailed acquisition target analysis, taking into consideration historical trend of the activity of players that have acquired other firms since 2015, and offering a means for other industry stakeholders to identify potential acquisition targets.
Chapter 11 features an in-depth analysis of more than 260 cell therapy developers that are anticipated to partner with contract research organizations and have been shortlisted on the basis of several relevant parameters, such as developer strength (which takes into account a company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of other cell therapy capabilities.
Chapter 12 features an in-depth analysis of more than 190 gene therapy developers that are anticipated to partner with contract research organizations and have been shortlisted on the basis of several relevant parameters, such as developer strength (which takes into account a company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of other gene therapy capabilities.
Chapter 13 features a comprehensive clinical trial analysis of ongoing clinical studies for the evaluation of various cell and gene therapy product candidates. The analysis provides details related to cell and gene therapy focused clinical studies being carried out across various geographies, based on the number of registered trials, year of trial, current trial status, current phase of development, key therapeutic areas (including indication-wise distribution), type of cell therapy (stem cells, T cells, dendritic cells, NK cells and tumor cells) and number of patients enrolled.
Chapter 14 features a comprehensive market forecast analysis, highlighting the likely growth of cell and gene therapy CROs market, for the time period 2021-2030. In order to provide details on the future outlook, our projections have been segmented on the basis of [A] type of therapy (cell therapy and gene therapy) [B] scale of operation (clinical and preclinical), [C] target therapeutic area (oncology and non-oncology) and [D] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA (Middle East and North Africa) and rest of the world).
Chapter 15 provides a detailed discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall cell and gene therapies research services industry.
Chapter 16 is a summary of the entire report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.
Chapter 17 is a collection of interview transcripts of the discussions that were held key stakeholders in the industry. The chapter provides details of interviews held with Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital) and Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado).
Chapter 18 is an appendix, which provides tabulated data and numbers for all the figures included in the report.
Chapter 19 is an appendix, which contains a list of companies and organizations mentioned in this report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Contract Research Organizations (CROs)
3.2.1. Evolution of CROs
3.2.2. Modern CROs and Prevalent Outsourcing Trends
3.3. Services Offered by CROs
3.4. Classification of CROs
3.5. Advantages of Outsourcing Operations to CROs
3.6. Risks Associated with Outsourcing to CROs
3.7. Role of CROs in the Development of Advanced Therapy Medicinal Products (ATMPs)
3.8. Future Perspectives
4. GUIDE TO OUTSOURCING
4.1. Chapter Overview
4.2. Outsourcing Cell and Gene Therapy Research
4.3. Guiding Models of Outsourcing
4.3.1. Transactional Outsourcing Model
4.3.2. Performance / Outcome-based Business Model
4.3.3. Staff Augmentation Model
4.3.4. Phase-Dependent Outsourcing Models
4.4. Selecting an Appropriate Outsourcing Model
4.4.1. Hybrid Approach
4.5. Selecting a CRO Partner
4.5.1 Key Considerations for Outsourcing Cell and Gene Therapy-related Operations
4.6. Role of CROs in Drug Development
4.6.1. Discovery and Preclinical Research
4.6.2. Early Clinical Research
4.6.3. Clinical Research and Laboratory Services
4.7. Conclusion
5. MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Cell and Gene Therapy CROs: Overall Market Landscape
5.2.1. Analysis by Year of Establishment, Company Size and Location of Headquarters
5.2.2. Analysis by Scale of Operation
5.3. Cell and Gene Therapy: Preclinical CROs
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size
5.3.3. Analysis by Location of Headquarters
5.3.4. Analysis by Type of Therapy
5.3.4.1. Analysis by Type of Cell Therapy
5.3.5. Analysis by Types of Services Offered
5.3.6. Analysis by Number of Services
5.3.7. Analysis by Services Offered and Type of Cell Therapy
5.4. Cell and Gene Therapy: Clinical CROs
5.4.1. Analysis by Year of Establishment
5.4.2. Analysis by Company Size
5.4.3. Analysis by Location of Headquarters
5.4.4. Analysis by Type of Therapy
5.4.4.1. Analysis by Type of Cell Therapy
5.4.5. Analysis by Types of Services Offered
5.4.6. Analysis by Number of Services
5.4.7. Analysis by Services Offered and Type of Cell Therapy
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Players based in North America
6.2.1. Altasciences
6.2.1.1. Company Overview
6.2.1.2. Services Portfolio
6.2.1.3. Future Outlook
6.2.2. CATO SMS
6.2.2.1. Company Overview
6.2.2.2. Services Portfolio
6.2.2.3. Future Outlook
6.2.3. Charles River Laboratories
6.2.3.1. Company Overview
6.2.3.2. Financial Information
6.2.3.3. Services Portfolio
6.2.3.3. Future Outlook
6.2.4. Covance
6.2.4.1. Company Overview
6.2.4.2. Financial Information
6.2.4.3. Services Portfolio
6.2.4.4. Future Outlook
6.2.5. Creative Biolabs
6.2.5.1. Company Overview
6.2.5.2. Services Portfolio
6.2.5.3. Future Outlook
6.2.6. IQVIA
6.2.6.1. Company Overview
6.2.6.2. Financial Information
6.2.6.3. Services Portfolio
6.2.6.4. Future Outlook
6.8.7. Medpace
6.8.7.1. Company Overview
6.8.7.2. Financial Information
6.8.7.3. Services Portfolio
6.8.7.4. Future Outlook
6.8.8. PPD
6.8.8.1. Company Overview
6.8.8.2. Services Portfolio
6.8.8.3. Future Outlook
6.8.9. Precision for Medicine
6.8.9.1. Company Overview
6.8.9.2. Services Portfolio
6.8.9.3. Future Outlook
6.8.10. QPS
6.8.10.1. Company Overview
6.8.10.2. Services Portfolio
6.8.10.3. Future Outlook
6.3. Players based in Europe
6.3.1. Accelera
6.3.1.1. Company Overview
6.3.1.2. Services Portfolio
6.3.1.3. Future Outlook
6.3.2. Evotec
6.3.2.1. Company Overview
6.3.2.2. Services Portfolio
6.3.2.3. Future Outlook
6.3.3. ICON
6.3.3.1. Company Overview
6.3.3.2. Services Portfolio
6.3.3.3. Future Outlook
6.3.4. JSB Solutions
6.3.4.1. Company Overview
6.3.4.2. Services Portfolio
6.3.4.3. Future Outlook
6.3.5. Quality Assistance
6.3.5.1. Company Overview
6.3.5.2. Financial Information
6.3.5.3. Services Portfolio
6.3.5.4. Future Outlook
6.4. Players based in Asia-Pacific
6.4.1. CMIC Group
6.4.1.1. Company Overview
6.4.1.2. Financial Information
6.4.1.3. Services Portfolio
6.4.1.4. Future Outlook
6.4.2. Pharmaseed
6.4.2.1. Company Overview
6.4.2.2. Services Portfolio
6.4.2.3. Future Outlook
7. BENCHMARK ANALYSIS
7.1. Chapter Overview
7.2. Methodology
7.3. Benchmark Analysis: Peer Groups
7.3.1. Peer Group I
7.3.2. Peer Group II
7.3.3. Peer Group III
7.3.4. Peer Group IV
7.3.5. Peer Group V
7.3.6. Peer Group VI
7.3.7. Peer Group VII
7.3.8. Peer Group VIII
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Cell and Gene Therapy CROs: Recent Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.2.1. Analysis by Year of Partnership and Type of Partnership
8.3.2.2. Analysis by Type of Partnership and Company Size
8.3.3. Analysis by Type of Therapy
8.3.3.1. Analysis by Year of Partnership and Type of Therapy
8.3.3.2. Analysis by Type of Partnership and Type of Therapy
8.3.4. Most Active Players: Analysis by Number of Partnerships
8.3.5. Regional Analysis
8.3.5.1. Intercontinental and Intracontinental Agreements
9. MERGERS AND ACQUISITIONS
9.1. Chapter Overview
9.2. Merger and Acquisition Models
9.3. Acquisition Models
9.4. Cell and Gene Therapy CROs: Mergers and Acquisitions
9.4.1. Analysis by Year
9.4.2. Analysis by Type of Acquisition
9.4.3. Analysis by Geography
9.4.3.1. Continent-Wise Distribution
9.4.3.2. Country-Wise Distribution
9.4.4. Intercontinental and Intracontinental Deals
9.4.5. Analysis by Key Value Drivers
9.4.6. Valuation Analysis: Acquisition Deal Multiples
9.4.7. Most Active Players: Analysis by Number of Acquisitions
10. KEY ACQUISITION TARGETS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Scoring Criteria and Key Assumptions
10.4. Potential Strategic Acquisition Targets for Mid-sized Players
10.5. Potential Strategic Acquisition Targets for Large Players
10.6. Potential Strategic Acquisition Targets for Very Large Players
10.7. Potential Strategic Acquisition Targets for Small Players
10.8. Concluding Remarks
11. LIKELY PARTNER ANALYSIS FOR CELL THERAPY CROs
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Potential Strategic Partners for Cell Therapy CROs
11.3.1. Likely Partner Opportunities for Stem Cell Therapy CROs
11.3.2. Likely Partner Opportunities for CAR-T Therapy CROs
11.3.3. Likely Partner Opportunities for Dendritic Cell Therapy CROs
11.3.4. Likely Partner Opportunities for Tumor Cell Therapy CROs
11.3.5. Likely Partner Opportunities for NK Cell Therapy CROs
12. LIKELY PARTNER ANALYSIS FOR GENE THERAPY CROs
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Potential Strategic Partners for Gene Therapy CROs
12.3.1. Likely Partner Opportunities in North America
12.3.2. Likely Partner Opportunities in Europe
12.3.3. Likely Partner Opportunities in Asia-Pacific
13. CLINICAL TRIAL ANALYSIS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Cell Therapies: Analysis by Number of Clinical Trials
13.3.1. Analysis by Trial Registration Year
13.3.2. Analysis by Trial Status
13.3.3. Analysis by Phase of Development
13.3.4. Analysis by Target Therapeutic Area
13.3.5. Analysis by Type of Sponsor
13.3.6. Analysis by Prominent Treatment Sites
13.3.7. Analysis by Geography
13.3.8. Analysis by Trial Registration Year and Geography
13.3.9. Analysis by Trial Status and Geography
13.3.10. Analysis by Trial Status, Trial Phase and Geography
13.3.11. Analysis by Therapeutic Area and Geography
13.4. Cell Therapies: Analysis by Enrolled Patient Population
13.4.1. Analysis by Trial Registration Year
13.4.2. Analysis by Trial Status
13.4.3. Analysis by Trial Phase
13.4.4. Analysis by Target Therapeutic Area
13.4.5. Analysis by Location of Trial Site
13.4.6. Analysis by Trial Status and Location of Trial Site
13.4.7. Analysis by Trial Status, Trial Phase and Location of Trial Site
13.4.8. Analysis by Therapeutic Area and Location of Trial Site
13.5. Gene Therapies: Analysis by Clinical Trials
13.5.1. Analysis by Trial Registration Year
13.5.2. Analysis by Trial Status
13.5.3. Analysis by Phase of Development
13.5.4. Analysis by Target Therapeutic Area
13.5.5. Analysis by Type of Sponsor
13.5.6. Analysis by Prominent Treatment Sites
13.5.7. Analysis by Geography
13.5.8. Analysis by Trial Registration Year and Geography
13.5.9. Analysis by Trial Status and Geography
13.5.10. Analysis by Trial Status, Trial Phase and Geography
13.5.11. Analysis by Therapeutic Area and Geography
13.6. Gene Therapy Clinical Trials: Analysis by Patients Enrolled
13.6.1. Analysis by Trial Registration Year
13.6.2. Analysis by Trial Status
13.6.3. Analysis by Trial Phase
13.6.4. Analysis by Therapeutic Area
13.6.5. Analysis by Location of Trial Site
13.6.6. Analysis by Trial Status and Location of Trial Site
13.6.7. Analysis by Trial Status, Trial Phase and Location of Trial Site
13.6.8. Analysis by Therapeutic Area and Location of Trial Site
14. MARKET FORECAST
14.1. Chapter Overview
14.2. Forecast Methodology and Key Assumptions
14.3. Global Cell and Gene Therapy CROs Market
14.3.1. Global Cell and Gene Therapy CROs Market: Distribution by Type of Therapy
14.3.2. Global Cell and Gene Therapy CROs Market: Distribution by Scale of Operation
14.3.3. Global Cell and Gene Therapy CROs Market: Distribution by Therapeutic Area
14.3.4. Global Cell and Gene Therapy CROs Market: Distribution by Geography
14.4. Cell Therapy CROs Market in North America
14.4.1. Cell Therapy CROs Market in North America: Distribution by Therapeutic Area
14.4.1.1. Cell Therapy CROs Market for Oncological Disorders in North America, 2020-2030
14.4.1.2. Cell Therapy CROs Market for Cardiovascular Disorders in North America, 2020-2030
14.4.1.3. Cell Therapy CROs Market for Inflammatory Disorders in North America, 2020-2030
14.4.1.4. Cell Therapy CROs Market for Neurological Disorders in North America, 2020-2030
14.4.1.5. Cell Therapy CROs Market for Other Therapeutic Areas in North America, 2020-2030
14.4.2. Cell Therapy CROs Market in North America: Distribution by Scale of Operation
14.4.2.1. Cell Therapy CROs Market for Clinical Operations in North America, 2020-2030
14.4.2.2. Cell Therapy CROs Market for Preclinical Operations in North America, 2020-2030
14.5. Cell Therapy CROs Market in Europe
14.5.1. Cell Therapy CROs Market in Europe: Distribution by Therapeutic Area
14.5.1.1. Cell Therapy CROs Market for Oncological Disorders in Europe, 2020-2030
14.5.1.2. Cell Therapy CROs Market for Cardiovascular Disorders in Europe, 2020-2030
14.5.1.3. Cell Therapy CROs Market for Inflammatory Disorders in Europe, 2020-2030
14.5.1.4. Cell Therapy CROs Market for Neurological Disorders in Europe, 2020-2030
14.5.1.5. Cell Therapy CROs Market for Other Therapeutic Areas in Europe, 2020-2030
14.5.2. Cell Therapy CROs Market in Europe: Distribution by Scale of Operation
14.5.2.1. Cell Therapy CROs Market for Clinical Operations in Europe, 2020-2030
14.5.2.2. Cell Therapy CROs Market for Preclinical Operations in Europe, 2020-2030
14.6. Cell Therapy CROs Market in Asia-Pacific
14.6.1. Cell Therapy CROs Market in Asia-Pacific: Distribution by Therapeutic Area
14.6.1.1. Cell Therapy CROs Market for Oncological Disorders in Asia-Pacific, 2020-2030
14.6.1.2. Cell Therapy CROs Market for Cardiovascular Disorders in Asia-Pacific, 2020-2030
14.6.1.3. Cell Therapy CROs Market for Inflammatory Disorders in Asia-Pacific, 2020-2030
14.6.1.4. Cell Therapy CROs Market for Neurological Disorders in Asia-Pacific, 2020-2030
14.6.1.5. Cell Therapy CROs Market for Other Therapeutic Areas in Asia-Pacific, 2020-2030
14.6.2. Cell Therapy CROs Market in Asia-Pacific: Distribution by Scale of Operation
14.6.2.1. Cell Therapy CROs Market for Clinical Operations in Asia-Pacific, 2020-2030
14.6.2.2. Cell Therapy CROs Market for Preclinical Operations in Asia-Pacific, 2020-2030
14.7. Cell Therapy CROs Market in Latin America
14.8. Cell Therapy CROs Market in Middle East North America
14.9. Cell Therapy CROs Market in Rest of the World
14.10. Gene Therapy CROs Market in North America
14.10.1. Gene Therapy CROs Market in North America: Distribution by Therapeutic Area
14.10.1.1. Gene Therapy CROs Market for Oncological Disorders in North America, 2020-2030
14.10.1.2. Gene Therapy CROs Market for Cardiovascular Disorders in North America, 2020-2030
14.10.1.3. Gene Therapy CROs Market for Inflammatory Disorders in North America, 2020-2030
14.10.1.4. Gene Therapy CROs Market for Neurological Disorders in North America, 2020-2030
14.10.1.5. Gene Therapy CROs Market for Other Therapeutic Areas in North America, 2020-2030
14.10.2. Gene Therapy CROs Market in North America: Distribution by Scale of Operation
14.10.2.1. Gene Therapy CROs Market for Clinical Operations in North America, 2020-2030
14.10.2.2. Gene Therapy CROs Market for Preclinical Operations in North America, 2020-2030
14.11. Gene Therapy CROs Market in Europe
14.11.1. Gene Therapy CROs Market in Europe: Distribution by Therapeutic Area
14.11.1.1. Gene Therapy CROs Market for Oncological Disorders in Europe, 2020-2030
14.11.1.2. Gene Therapy CROs Market for Cardiovascular Disorders in Europe, 2020-2030
14.11.1.3. Gene Therapy CROs Market for Inflammatory Disorders in Europe, 2020-2030
14.11.1.4. Gene Therapy CROs Market for Neurological Disorders in Europe, 2020-2030
14.11.1.5. Gene Therapy CROs Market for Other Therapeutic Areas in Europe, 2020-2030
14.11.2. Gene Therapy CROs Market in Europe: Distribution by Scale of Operation
14.11.2.1. Gene Therapy CROs Market for Clinical Operations in Europe, 2020-2030
14.11.2.2. Gene Therapy CROs Market for Preclinical Operations in Europe, 2020-2030
14.12. Gene Therapy CROs Market in Asia-Pacific
14.12.1. Gene Therapy CROs Market in Asia-Pacific: Distribution by Therapeutic Area
14.12.1.1. Gene Therapy CROs Market for Oncological Disorders in Asia-Pacific, 2020-2030
14.12.1.2. Gene Therapy CROs Market for Cardiovascular Disorders in Asia-Pacific, 2020-2030
14.12.1.3. Gene Therapy CROs Market for Inflammatory Disorders in Asia-Pacific, 2020-2030
14.12.1.4. Gene Therapy CROs Market for Neurological Disorders in Asia-Pacific, 2020-2030
14.12.1.5. Gene Therapy CROs Market for Other Therapeutic Areas in Asia-Pacific, 2020-2030
14.12.2. Gene Therapy CROs Market in Asia-Pacific: Distribution by Scale of Operation
14.12.2.1. Gene Therapy CROs Market for Clinical Operations in Asia-Pacific, 2020-2030
14.12.2.2. Gene Therapy CROs Market for Preclinical Operations in Asia-Pacific, 2020-2030
14.13. Gene Therapy CROs Market in Latin America
14.14. Gene Therapy CROs Market in Middle East North America
14.15. Gene Therapy CROs Market in Rest of the World
14.16. Concluding Remarks
15. SWOT ANALYSIS
15.1. Chapter Overview
15.2. Strengths
15.3. Weaknesses
15.4. Opportunities
15.5. Threats
15.6. Comparison of SWOT Factors
16. CONCLUSION
17. INTERVIEW AND SURVEY TRANSCRIPTS
17.1. Chapter Overview
17.2. CATO SMS
17.2.1. Company Snapshot
17.2.2. Survey Transcript: Jessica Bliven, Director, Marketing and Sales
17.3. Diamond Pharma Services
17.3.1. Company Snapshot
17.3.2. Survey Transcript: Roley Davis, Business Development Manager
17.4. Changhai Hospital, Second Military Medical University
17.4.1. University Snapshot
17.4.2. Survey Transcript: Xian-Bao Zhan, Professor of Medicine, Director, Department of Oncology
17.5. University of Colorado
17.5.1. University Snapshot
17.5.2. Survey Transcript: Enkhtsetseg Purev, Assistant Professor of Medicine
18. APPENDIX I: TABULATED DATA
19. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 Stages of the Drug Development Process
Figure 3.2 Services Offered by CROs
Figure 3.3 Advantages of Outsourcing Operations to CROs
Figure 3.4 Risks Associated with Outsourcing to CROs
Figure 3.5 Classification of ATMPs
Figure 3.6 Types of Cells Incorporated in Cell Therapy Medicinal Products (CTMPs)
Figure 4.1 Guiding Models of Outsourcing
Figure 4.2 Key Characteristics of Transactional Outsourcing Model
Figure 4.3 Key Characteristics of Performance / Outcome-based Business Model
Figure 4.5 Key Considerations for Selecting a CRO Partner
Figure 4.6 Role of CROs Across Different Phases of Drug Development
Figure 5.1 Cell and Gene Therapy CROs: Distribution by Year of Establishment, Company Size and Location of Headquarters
Figure 5.2 Cell and Gene Therapy CROs: Distribution by Scale of Operation
Figure 5.3 Cell and Gene Therapy Preclinical CROs: Distribution by Year of Establishment
Figure 5.4 Cell and Gene Therapy Preclinical CROs: Distribution by Company Size
Figure 5.5 Cell and Gene Therapy Preclinical CROs Distribution by Location of Headquarters
Figure 5.6 Cell and Gene Therapy Preclinical CROs: Distribution by Types of Therapies
Figure 5.7 Cell and Gene Therapy Preclinical CROs: Distribution by Types of Cell Therapies
Figure 5.8 Cell and Gene Therapy Preclinical CROs: Distribution by Types of Services Offered
Figure 5.9 Cell and Gene Therapy Preclinical CROs: Distribution by Number of Services Offered
Figure 5.10 Cell and Gene Therapy Preclinical CROs: Distribution by Types of Services Offered and Types of Therapies
Figure 5.11 Cell and Gene Therapy Clinical CROs: Distribution by Year of Establishment
Figure 5.12 Cell and Gene Therapy Clinical CROs: Distribution by Company Size
Figure 5.13 Cell and Gene Therapy Clinical CROs: Distribution by Location of Headquarters
Figure 5.14 Cell and Gene Therapy Clinical CROs: Distribution by Types of Therapies
Figure 5.15 Cell and Gene Therapy Clinical CROs: Distribution by Types of Cell Therapies
Figure 5.16 Cell and Gene Therapy Clinical CROs: Distribution by Types of Services Offered
Figure 5.17 Cell and Gene Therapy Clinical CROs: Distribution by Number of Services Offered
Figure 5.18 Cell and Gene Therapy Clinical CROs: Distribution by Type of Services Offered and Type of Therapies
Figure 6.1 Altasciences: Services Portfolio
Figure 6.2 CATO SMS: Services Portfolio
Figure 6.3 Charles River Laboratories: Annual Revenues, 2015-2020 (USD Billion)
Figure 6.4 Charles River Laboratories: Services Portfolio
Figure 6.5 Covance: Annual Revenues, 2015 - 9M 2020 (USD Billion)
Figure 6.6 Covance: Non-clinical Services Portfolio
Figure 6.7 Covance: Clinical Services Portfolio
Figure 6.8 Creative Biolabs: Services Portfolio for CAR-T Therapy Development
Figure 6.9 Creative Biolabs: Services Portfolio for TCR Therapy Development
Figure 6.10 IQVIA: Annual Revenues, 2015-2020 (USD Billion)
Figure 6.11 IQVIA: Distribution of Annual Revenue by Operating Business Segments (2019)
Figure 6.12 IQVIA: Services Portfolio
Figure 6.13 Medpace: Annual Revenues, 2015-2020 (USD Million)
Figure 6.14 Medpace: Services Portfolio
Figure 6.15 Medpace: Regulatory Affair Capabilities
Figure 6.16 PPD: Services Portfolio
Figure 6.17 Precision for Medicine: Services Portfolio
Figure 6.18 QPS: Services Portfolio
Figure 6.19 Accelera: Areas of Expertise
Figure 6.20 Evotec: Areas of Expertise
Figure 6.21 ICON: Services Portfolio
Figure 6.22 JSB Solutions: Services Portfolio
Figure 6.23 Quality Assistance: Annual Revenues, 2015-2019 (EUR Million)
Figure 6.24 Quality Assistance: Services Portfolio
Figure 6.25 CMIC Group: Annual Revenues, 2015-9M 2020 (JPY Billion)
Figure 6.26 CMIC Group: Non-clinical Services Portfolio
Figure 6.27 CMIC Group: Clinical Services Portfolio
Figure 6.28 Pharmaseed: Services Portfolio
Figure 7.1 Benchmark Analysis: Distribution by Location of Headquarter and Company Size
Figure 7.2 Benchmark Analysis: Peer Group I
Figure 7.3 Benchmark Analysis: Peer Group II
Figure 7.4 Benchmark Analysis: Peer Group III
Figure 7.5 Benchmark Analysis: Peer Group IV
Figure 7.6 Benchmark Analysis: Peer Group V
Figure 7.7 Benchmark Analysis: Peer Group VI
Figure 7.8 Benchmark Analysis: Peer Group VII
Figure 7.9 Benchmark Analysis: Peer Group VIII
Figure 8.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Figure 8.5 Partnerships and Collaborations: Distribution by Types of Therapies
Figure 8.6 Partnerships and Collaborations: Distribution by Year of Partnership and Types of Therapies
Figure 8.7 Partnerships and Collaborations: Distribution by Type of Partnership and Types of Therapies
Figure 8.8 Most Active Players: Distribution by Number of Partnerships
Figure 8.9 Partnerships and Collaborations: Continent-Wise Distribution
Figure 8.10 Partnerships and Collaborations: Country-Wise Distribution
Figure 9.1 Mergers and Acquisitions: Distribution by Year
Figure 9.2 Mergers and Acquisitions: Distribution by Type of Acquisition
Figure 9.3 Mergers and Acquisitions: Continent-Wise Distribution
Figure 9.4 Mergers and Acquisitions: Country-Wise Distribution
Figure 9.5 Mergers and Acquisitions: Intercontinental and Intracontinental Deals
Figure 9.6 Mergers and Acquisitions: Distribution by Key Value Drivers
Figure 9.7 Valuation Analysis: Distribution by Acquisition Deal Multiples
Figure 9.8 Most Active Players: Distribution by Number of Acquisitions
Figure 13.1 Clinical Trial Analysis: Scope and Methodology
Figure 13.2 Clinical Trial Analysis for Cell Therapies: Distribution by Number of Clinical Trials
Figure 13.3 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Registration Year
Figure 13.4 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Status
Figure 13.5 Clinical Trial Analysis for Cell Therapies: Distribution by Phase of Development
Figure 13.6 Clinical Trial Analysis for Cell Therapies: Distribution by Target Therapeutic Area
Figure 13.7 Clinical Trial Analysis for Cell Therapies: Distribution by Type of Sponsor
Figure 13.8 Clinical Trial Analysis for Cell Therapies: Distribution by Prominent Treatment Sites
Figure 13.9 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Site
Figure 13.10 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Registration Year and Geography
Figure 13.11 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Status and Geography
Figure 13.12 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Status, Trial Phase and Geography
Figure 13.13 Clinical Trial Analysis for Cell Therapies: Distribution by Therapeutic Area and Geography
Figure 13.14 Clinical Trial Analysis for Cell Therapies: Distribution by Enrolled Patient Population
Figure 13.15 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Registration Year
Figure 13.16 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Status
Figure 13.17 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Phase
Figure 13.18 Clinical Trial Analysis for Cell Therapies: Distribution by Target Therapeutic Area
Figure 13.19 Clinical Trial Analysis for Cell Therapies: Distribution by Enrolled Patient Population and Location of Trial Site
Figure 13.20 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Status and Location of Trial Site
Figure 13.21 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Status, Trial Phase and Location of Trial Site
Figure 13.22 Clinical Trial Analysis for Cell Therapies: Distribution by Therapeutic Area and Location of Trial Site
Figure 13.23 Clinical Trial Analysis for Gene Therapies: Distribution by Number of Clinical Trials
Figure 13.24 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Registration Year
Figure 13.25 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Status
Figure 13.26 Clinical Trial Analysis for Gene Therapies: Distribution by Phase of Development
Figure 13.27 Clinical Trial Analysis for Gene Therapies: Distribution by Target Therapeutic Area
Figure 13.28 Clinical Trial Analysis for Gene Therapies: Distribution by Type of Sponsor
Figure 13.29 Clinical Trial Analysis for Gene Therapies: Distribution by Prominent Treatment Sites
Figure 13.30 Clinical Trial Analysis for Gene Therapies: Distribution by Location of Trial Site
Figure 13.31 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Registration Year and Geography
Figure 13.32 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Status and Geography
Figure 13.33 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Status, Trial Phase and Geography
Figure 13.34 Clinical Trial Analysis for Gene Therapies: Distribution by Therapeutic Area and Geography
Figure 13.35 Clinical Trial Analysis for Gene Therapies: Distribution by Enrolled Patient Population
Figure 13.36 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Registration Year
Figure 13.37 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Status
Figure 13.38 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Phase
Figure 13.39 Clinical Trial Analysis for Gene Therapies: Distribution by Target Therapeutic Area
Figure 13.40 Clinical Trial Analysis for Gene Therapies: Distribution by Enrolled Patient Population and Location of Trial Site
Figure 13.41 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Status and Location of Trial Site
Figure 13.42 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Status, Trial Phase and Location of Trial Site
Figure 13.43 Clinical Trial Analysis for Gene Therapies: Distribution by Therapeutic Area and Location of Trial Site
Figure 14.1 Cell and Gene Therapy CROs: Market Forecast Methodology
Figure 14.2 Global Cell and Gene Therapy CROs Market, 2021-2030
Figure 14.3 Global Cell and Gene Therapy CROs Market: Distribution by Type of Therapy, 2021 and 2030
Figure 14.4 Global Cell and Gene Therapy CROs Market: Distribution by Scale of Operation, 2021 and 2030
Figure 14.5 Global Cell and Gene Therapy CROs Market: Distribution by Therapeutic Area, 2021 and 2030
Figure 14.6 Global Cell and Gene Therapy CROs Market: Distribution by Geography, 2021 and 2030
Figure 14.7 Cell Therapy CROs Market in North America, 2021-2030 (USD Million)
Figure 14.8 Cell Therapy CROs Market for Oncological Disorders in North America, 2021-2030 (USD Million)
Figure 14.9 Cell Therapy CROs Market for Cardiovascular Disorders in North America, 2021-2030 (USD Million)
Figure 14.10 Cell Therapy CROs Market for Inflammatory Disorders in North America, 2021-2030 (USD Million)
Figure 14.11 Cell Therapy CROs Market for Neurological Disorders in North America, 2021-2030 (USD Million)
Figure 14.12 Cell Therapy CROs Market for Other Therapeutic Areas in North America, 2021-2030 (USD Million)
Figure 14.13 Cell Therapy CROs Market for Clinical Operations in North America, 2021-2030 (USD Million)
Figure 14.14 Cell Therapy CROs Market for Preclinical Operations in North America, 2021-2030 (USD Million)
Figure 14.15 Cell Therapy CROs Market in Europe, 2021-2030 (USD Million)
Figure 14.16 Cell Therapy CROs Market for Oncological Disorders in Europe, 2021-2030 (USD Million)
Figure 14.17 Cell Therapy CROs Market for Cardiovascular Disorders in Europe, 2021-2030 (USD Million)
Figure 14.18 Cell Therapy CROs Market for Inflammatory Disorders in Europe, 2021-2030 (USD Million)
Figure 14.19 Cell Therapy CROs Market for Neurological Disorders in Europe, 2021-2030 (USD Million)
Figure 14.20 Cell Therapy CROs Market for Other Therapeutic Areas in Europe, 2021-2030 (USD Million)
Figure 14.21 Cell Therapy CROs Market for Clinical Operations in Europe, 2021-2030 (USD Million)
Figure 14.22 Cell Therapy CROs Market for Preclinical Operations in Europe, 2021-2030 (USD Million)
Figure 14.23 Cell Therapy CROs Market in Asia-Pacific, 2021-2030 (USD Million)
Figure 14.24 Cell Therapy CROs Market for Oncological Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 14.25 Cell Therapy CROs Market for Cardiovascular Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 14.26 Cell Therapy CROs Market for Inflammatory Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 14.27 Cell Therapy CROs Market for Neurological Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 14.28 Cell Therapy CROs Market for Other Therapeutic Areas in Asia-Pacific, 2021-2030 (USD Million)
Figure 14.29 Cell Therapy CROs Market for Clinical Operations in Asia-Pacific, 2021-2030 (USD Million)
Figure 14.30 Cell Therapy CROs Market for Preclinical Operations in Asia-Pacific, 2021-2030 (USD Million)
Figure 14.31 Cell Therapy CROs Market in Latin America, 2021-2030 (USD Million)
Figure 14.32 Cell Therapy CROs Market in Middle East North America, 2021-2030 (USD Million)
Figure 14.33 Cell Therapy CROs Market in Rest of the World, 2021-2030 (USD Million)
Figure 14.34 Cell Therapy CROs Market: Conservative, Base and Optimistic Scenarios, 2020, 2025 and 2030 (USD Million)
Figure 14.35 Gene Therapy CROs Market in North America, 2021-2030 (USD Million)
Figure 14.36 Gene Therapy CROs Market for Oncological Disorders in North America, 2021-2030 (USD Million)
Figure 14.37 Gene Therapy CROs Market for Cardiovascular Disorders in North America, 2021-2030 (USD Million)
Figure 14.38 Gene Therapy CROs Market for Inflammatory Disorders in North America, 2021-2030 (USD Million)
Figure 14.39 Gene Therapy CROs Market for Neurological Disorders in North America, 2021-2030 (USD Million)
Figure 14.40 Gene Therapy CROs Market for Other Therapeutic Areas in North America, 2021-2030 (USD Million)
Figure 14.41 Gene Therapy CROs Market for Clinical Operations in North America, 2021-2030 (USD Million)
Figure 14.42 Gene Therapy CROs Market for Preclinical Operations in North America, 2021-2030 (USD Million)
Figure 14.43 Gene Therapy CROs Market in Europe, 2021-2030 (USD Million)
Figure 14.44 Gene Therapy CROs Market for Oncological Disorders in Europe, 2021-2030 (USD Million)
Figure 14.45 Gene Therapy CROs Market for Cardiovascular Disorders in Europe, 2021-2030 (USD Million)
Figure 14.46 Gene Therapy CROs Market for Inflammatory Disorders in Europe, 2021-2030 (USD Million)
Figure 14.47 Gene Therapy CROs Market for Neurological Disorders in Europe, 2021-2030 (USD Million)
Figure 14.48 Gene Therapy CROs Market for Other Therapeutic Areas in Europe, 2021-2030 (USD Million)
Figure 14.49 Gene Therapy CROs Market for Clinical Operations in Europe, 2021-2030 (USD Million)
Figure 14.50 Gene Therapy CROs Market for Preclinical Operations in Europe, 2021-2030 (USD Million)
Figure 14.51 Gene Therapy CROs Market in Asia-Pacific, 2021-2030 (USD Million)
Figure 14.52 Gene Therapy CROs Market for Oncological Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 14.53 Gene Therapy CROs Market for Cardiovascular Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 14.54 Gene Therapy CROs Market for Inflammatory Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 14.55 Gene Therapy CROs Market for Neurological Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 14.56 Gene Therapy CROs Market for Other Therapeutic Areas in Asia-Pacific, 2021-2030 (USD Million)
Figure 14.57 Gene Therapy CROs Market for Clinical Operations in Asia-Pacific, 2021-2030 (USD Million)
Figure 14.58 Gene Therapy CROs Market for Preclinical Operations in Asia-Pacific, 2021-2030 (USD Million)
Figure 14.59 Gene Therapy CROs Market in Latin America, 2021-2030 (USD Million)
Figure 14.60 Gene Therapy CROs Market in Middle East North America, 2021-2030 (USD Million)
Figure 14.61 Gene Therapy CROs Market in Rest of the World, 2021-2030 (USD Million)
Figure 14.62 Gene Therapy CROs Market: Conservative, Base and Optimistic Scenarios, 2020, 2025 and 2030 (USD Million)
Figure 15.1 Cell and Gene Therapy CROs SWOT Analysis: Overview
Figure 15.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 16.1 Concluding Remarks: Current Market Landscape for Preclinical Cell and Gene Therapy CROs
Figure 16.2 Concluding Remarks: Current Market Landscape for Clinical Cell and Gene Therapy CROs
Figure 16.3 Concluding Remarks: Recent Partnerships
Figure 16.4 Concluding Remarks: Mergers and Acquisitions
Figure 16.5 Concluding Remarks: Clinical Trial Analysis
Figure 16.6 Concluding Remarks: Market Sizing and Opportunity Analysis
Table 3.1 List of Approved ATMP Products
Table 4.1 Attributes of Transactional Outsourcing-based Business Model
Table 5.1 Cell and Gene Therapy CROs Offering Preclinical Services: Information on Year of Establishment, Location of Headquarters, Company Size and Types of Therapies
Table 5.2 Cell and Gene Therapy CROs Offering Preclinical Services: Information on Types of Preclinical Services Offered
Table 5.3 Cell and Gene Therapy CROs Offering Clinical Services: Information on Year of Establishment, Location of Headquarters, Company Size, Types of Therapies
Table 5.4 Cell and Gene Therapy CROs Offering Clinical Services: Information on Types of Clinical Services Offered
Table 5.5 Cell and Gene Therapy CROs: Information on Regulatory Accreditations Received
Table 6.1 Altasciences: Company Overview
Table 6.2 Altasciences: Future Outlook
Table 6.3 CATO SMS: Company Overview
Table 6.4 CATO SMS: Future Outlook
Table 6.5 Charles River Laboratories: Company Overview
Table 6.6 Charles River Laboratories: Future Outlook
Table 6.7 Covance: Company Overview
Table 6.8 Covance: Future Outlook
Table 6.9 Creative Biolabs: Company Overview
Table 6.10 IQVIA: Company Overview
Table 6.11 IQVIA: Future Outlook
Table 6.12 Medpace: Company Overview
Table 6.13 Medpace: Future Outlook
Table 6.14 PPD: Company Overview
Table 6.15 PPD: Future Outlook
Table 6.16 Precision for Medicine: Company Overview
Table 6.17 Precision for Medicine: Future Outlook
Table 6.18 QPS: Company Overview
Table 6.19 QPS: Future Outlook
Table 6.20 Accelera: Company Overview
Table 6.21 Evotec: Company Overview
Table 6.22 Evotec: Future Outlook
Table 6.23 ICON: Company Overview
Table 6.24 ICON: Future Outlook
Table 6.25 JSB Solutions: Company Overview
Table 6.26 Quality Assistance: Company Overview
Table 6.27 CMIC Group: Company Overview
Table 6.28 CMIC Group: Future Outlook
Table 6.29 Pharmaseed: Company Overview
Table 7.1 Benchmark Analysis: Peer Groups
Table 8.1 Partnerships and Collaborations: Information on Partner, Year of Partnership, Type of Partnership and Types of Therapies, 2015-2020
Table 9.1 Cell and Gene Therapy CROs: List of Mergers and Acquisitions, 2015–2020
Table 9.2 Cell and Gene Therapy CROs Mergers and Acquisitions: Information on Key Value Drivers and Type of Therapy, 2015 - 2020
Table 10.1 Potential Strategic Acquisition Targets: Mid-size Players
Table 10.2 Potential Strategic Acquisition Targets: Large Players
Table 10.3 Potential Strategic Acquisition Targets: Very Large Players
Table 10.4 Potential Strategic Acquisition Targets: Small Players
Table 11.1 Likely Partners for Stem Cell Therapy CROs
Table 11.2 Likely Partners for CAR-T Therapy CROs
Table 11.3 Likely Partners for Dendritic Cell Therapy CROs
Table 11.4 Likely Partners for Tumor Cell Therapy CROs
Table 11.5 Likely Partners for NK Cell Therapy CROs
Table 12.1 Likely Partner Opportunities for Gene Therapy in North America
Table 12.2 Likely Partner Opportunities for Gene Therapy in Europe
Table 12.3 Likely Partner Opportunities for Gene Therapy in Asia-Pacific
Table 13.1 Clinical Trial Analysis: Emerging Molecules
Table 13.2 Clinical Trial Analysis: Most Important Trials
Table 17.1 CATO SMS: Company Snapshot
Table 17.2 Changhai Hospital, Second Military Medical University: University Snapshot
Table 17.3 University of Colorado: University Snapshot
Table 18.1 Cell and Gene Therapy CROs: Distribution by Year of Establishment, Company Size and Location of Headquarters
Table 18.2 Cell and Gene Therapy CROs: Distribution by Scale of Operation
Table 18.3 Cell and Gene Therapy Preclinical CROs: Distribution by Year of Establishment
Table 18.4 Cell and Gene Therapy Preclinical CROs: Distribution by Company Size
Table 18.5 Cell and Gene Therapy Preclinical CROs: Distribution by Location of Headquarters
Table 18.6 Cell and Gene Therapy Preclinical CROs: Distribution by Types of Therapies
Table 18.7 Cell and Gene Therapy Preclinical CROs: Distribution by Types of Cell Therapies
Table 18.8 Cell and Gene Therapy Preclinical CROs: Distribution by Types of Services Offered
Table 18.9 Cell and Gene Therapy Preclinical CROs: Distribution by Number of Services Offered
Table 18.10 Cell and Gene Therapy Preclinical CROs: Distribution by Types of Services Offered and Types of Therapies
Table 18.11 Cell and Gene Therapy Clinical CROs: Distribution by Year of Establishment
Table 18.12 Cell and Gene Therapy Clinical CROs: Distribution by Company Size
Table 18.13 Cell and Gene Therapy Clinical CROs: Distribution by Location of Headquarters
Table 18.14 Cell and Gene Therapy Clinical CROs: Distribution by Types of Therapies
Table 18.15 Cell and Gene Therapy Clinical CROs: Distribution by Types of Cell Therapies
Table 18.16 Cell and Gene Therapy Clinical CROs: Distribution by Types of Services Offered
Table 18.17 Cell and Gene Therapy Clinical CROs: Distribution by Number of Services Offered
Table 18.18 Cell and Gene Therapy Clinical CROs: Distribution by Types of Services Offered and Type of Therapies
Table 18.19 Charles River Laboratories: Annual Revenues, 2015-9M 2020 (USD Billion)
Table 18.20 Covance: Annual Revenues, 2015-Q3 2020 (USD Billion)
Table 18.21 IQVIA: Annual Revenues, 2015-2020 (USD Billion)
Table 18.22 IQVIA: Distribution of Annual Revenue by Operating Business Segments (2019)
Table 18.23 Medpace: Annual Revenues, 2015-2020 (USD Million)
Table 18.24 Quality Assistance: Annual Revenues, 2015 – 2019 (EUR Million)
Table 18.25 CMIC Group: Annual Revenues, 2015-9M 2020 (JPY Billion)
Table 18.26 Partnerships and Collaborations: Distribution by Year of Partnership
Table 18.27 Partnerships and Collaborations: Distribution by Type of Partnership
Table 18.28 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Table 18.29 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Table 18.30 Partnerships and Collaborations: Distribution by Types of Therapies
Table 18.31 Partnerships and Collaborations: Distribution by Year of Partnership and Types of Therapies
Table 18.32 Partnerships and Collaborations: Distribution by Type of Partnership and Types of Therapies
Table 18.33 Most Active Players: Distribution by Number of Partnerships
Table 18.34 Partnerships and Collaborations: Continent-Wise Distribution
Table 18.35 Partnerships and Collaborations: Country-Wise Distribution
Table 18.36 Mergers and Acquisitions: Distribution by Year
Table 18.37 Mergers and Acquisitions: Distribution by Type of Acquisition
Table 18.38 Mergers and Acquisitions: Continent-Wise Distribution
Table 18.39 Mergers and Acquisitions: Country-Wise Distribution
Table 18.40 Mergers and Acquisitions: Intercontinental and Intracontinental Deals
Table 18.41 Mergers and Acquisitions: Distribution by Key Value Drivers
Table 18.42 Valuation Analysis: Distribution by Deal Multiples
Table 18.43 Most Active Players: Distribution by Number of Acquisitions
Table 18.44 Clinical Trial Analysis for Cell Therapies: Distribution by Number of Clinical Trials
Table 18.45 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Registration Year
Table 18.46 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Status
Table 18.47 Clinical Trial Analysis for Cell Therapies: Distribution by Phase of Development
Table 18.48 Clinical Trial Analysis for Cell Therapies: Distribution by Target Therapeutic Area
Table 18.49 Clinical Trial Analysis for Cell Therapies: Distribution by Type of Sponsor
Table 18.50 Clinical Trial Analysis for Cell Therapies: Distribution by Prominent Treatment Sites
Table 18.51 Clinical Trial Analysis for Cell Therapies: Distribution by Geography
Table 18.52 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Registration Year and Geography
Table 18.53 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Status and Geography
Table 18.54 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Status, Trial Phase and Geography
Table 18.55 Clinical Trial Analysis for Cell Therapies: Distribution by Therapeutic Area and Geography
Table 18.56 Clinical Trial Analysis for Cell Therapies: Distribution by Enrolled Patient Population
Table 18.57 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Registration Year
Table 18.58 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Status
Table 18.59 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Phase
Table 18.60 Clinical Trial Analysis for Cell Therapies: Distribution by Target Therapeutic Area
Table 18.61 Clinical Trial Analysis for Cell Therapies: Distribution by Location of Trial Site
Table 18.62 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Status and Location of Trial Site
Table 18.63 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Status, Trial Phase and Location of Trial Site
Table 18.64 Clinical Trial Analysis for Cell Therapies: Distribution by Therapeutic Area and Location of Trial Site
Table 18.65 Clinical Trial Analysis for Gene Therapies: Distribution by Number of Clinical Trials
Table 18.66 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Registration Year
Table 18.67 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Status
Table 18.68 Clinical Trial Analysis for Gene Therapies: Distribution by Phase of Development
Table 18.69 Clinical Trial Analysis for Gene Therapies: Distribution by Target Therapeutic Area
Table 18.70 Clinical Trial Analysis for Gene Therapies: Distribution by Type of Sponsor
Table 18.71 Clinical Trial Analysis for Gene Therapies: Distribution by Prominent Treatment Sites
Table 18.72 Clinical Trial Analysis for Gene Therapies: Distribution by Geography
Table 18.73 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Registration Year and Geography
Table 18.74 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Status and Geography
Table 18.75 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Status, Trial Phase and Geography
Table 18.76 Clinical Trial Analysis for Gene Therapies: Distribution by Therapeutic Area and Geography
Table 18.77 Clinical Trial Analysis for Gene Therapies: Distribution by Enrolled Patient Population
Table 18.78 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Registration Year
Table 18.79 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Status
Table 18.80 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Phase
Table 18.81 Clinical Trial Analysis for Gene Therapies: Distribution by Target Therapeutic Area
Table 18.82 Clinical Trial Analysis for Gene Therapies: Distribution by Location of Trial Site
Table 18.83 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Status and Location of Trial Site
Table 18.84 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Status, Trial Phase and Location of Trial Site
Table 18.85 Clinical Trial Analysis for Gene Therapies: Distribution by Therapeutic Area and Location of Trial Site
Table 18.86 Global Cell and Gene Therapy CROs Market, 2021-2030
Table 18.87 Global Cell and Gene Therapy CROs Market: Distribution by Type of Therapy, 2021 and 2030
Table 18.88 Global Cell and Gene Therapy CROs Market: Distribution by Scale of Operation, 2021 and 2030
Table 18.89 Global Cell and Gene Therapy CROs Market: Distribution by Therapeutic Area, 2021 and 2030
Table 18.90 Global Cell and Gene Therapy CROs Market: Distribution by Geography, 2021 and 2030
Table 18.91 Cell Therapy CROs Market in North America, 2021-2030 (USD Million)
Table 18.92 Cell Therapy CROs Market for Oncological Disorders in North America, 2021-2030 (USD Million)
Table 18.93 Cell Therapy CROs Market for Cardiovascular Disorders in North America, 2021-2030 (USD Million)
Table 18.94 Cell Therapy CROs Market for Inflammatory Disorders in North America, 2021-2030 (USD Million)
Table 18.95 Cell Therapy CROs Market for Neurological Disorders in North America, 2021-2030 (USD Million)
Table 18.96 Cell Therapy CROs Market for Other Therapeutic Areas in North America, 2021-2030 (USD Million)
Table 18.97 Cell Therapy CROs Market for Clinical Operations in North America, 2021-2030 (USD Million)
Table 18.98 Cell Therapy CROs Market for Preclinical Operations in North America, 2021-2030 (USD Million)
Table 18.99 Cell Therapy CROs Market in Europe, 2021-2030 (USD Million)
Table 18.100 Cell Therapy CROs Market for Oncological Disorders in Europe, 2021-2030 (USD Million)
Table 18.101 Cell Therapy CROs Market for Cardiovascular Disorders in Europe, 2021-2030 (USD Million)
Table 18.102 Cell Therapy CROs Market for Inflammatory Disorders in Europe, 2021-2030 (USD Million)
Table 18.103 Cell Therapy CROs Market for Neurological Disorders in Europe, 2021-2030 (USD Million)
Table 18.104 Cell Therapy CROs Market for Other Therapeutic Areas in Europe, 2021-2030 (USD Million)
Table 18.105 Cell Therapy CROs Market for Clinical Operations in Europe, 2021-2030 (USD Million)
Table 18.106 Cell Therapy CROs Market for Preclinical Operations in Europe, 2021-2030 (USD Million)
Table 18.107 Cell Therapy CROs Market in Asia-Pacific, 2021-2030 (USD Million)
Table 18.108 Cell Therapy CROs Market for Oncological Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 18.109 Cell Therapy CROs Market for Cardiovascular Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 18.110 Cell Therapy CROs Market for Inflammatory Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 18.111 Cell Therapy CROs Market for Neurological Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 18.112 Cell Therapy CROs Market for Other Therapeutic Areas in Asia-Pacific, 2021-2030 (USD Million)
Table 18.113 Cell Therapy CROs Market for Clinical Operations in Asia-Pacific, 2021-2030 (USD Million)
Table 18.114 Cell Therapy CROs Market for Preclinical Operations in Asia-Pacific, 2021-2030 (USD Million)
Table 18.115 Cell Therapy CROs Market in Latin America, 2021-2030 (USD Million)
Table 18.116 Cell Therapy CROs Market in Middle East North America, 2021-2030 (USD Million)
Table 18.117 Cell Therapy CROs Market in Rest of the World, 2021-2030 (USD Million)
Table 18.118 Cell Therapy CROs Market: Conservative, Base and Optimistic Scenarios, 2020, 2025 and 2030 (USD Million)
Table 18.119 Gene Therapy CROs Market in North America, 2021-2030 (USD Million)
Table 18.120 Gene Therapy CROs Market for Oncological Disorders in North America, 2021-2030 (USD Million)
Table 18.121 Gene Therapy CROs Market for Cardiovascular Disorders in North America, 2021-2030 (USD Million)
Table 18.122 Gene Therapy CROs Market for Inflammatory Disorders in North America, 2021-2030 (USD Million)
Table 18.123 Gene Therapy CROs Market for Neurological Disorders in North America, 2021-2030 (USD Million)
Table 18.124 Gene Therapy CROs Market for Other Therapeutic Areas in North America, 2021-2030 (USD Million)
Table 18.125 Gene Therapy CROs Market for Clinical Operations in North America, 2021-2030 (USD Million)
Table 18.126 Gene Therapy CROs Market for Preclinical Operations in North America, 2021-2030 (USD Million)
Table 18.127 Gene Therapy CROs Market in Europe, 2021-2030 (USD Million)
Table 18.128 Gene Therapy CROs Market for Oncological Disorders in Europe, 2021-2030 (USD Million)
Table 18.129 Gene Therapy CROs Market for Cardiovascular Disorders in Europe, 2021-2030 (USD Million)
Table 18.130 Gene Therapy CROs Market for Inflammatory Disorders in Europe, 2021-2030 (USD Million)
Table 18.131 Gene Therapy CROs Market for Neurological Disorders in Europe, 2021-2030 (USD Million)
Table 18.132 Gene Therapy CROs Market for Other Therapeutic Areas in Europe, 2021-2030 (USD Million)
Table 18.133 Gene Therapy CROs Market for Clinical Operations in Europe, 2021-2030 (USD Million)
Table 18.134 Gene Therapy CROs Market for Preclinical Operations in Europe, 2021-2030 (USD Million)
Table 18.135 Gene Therapy CROs Market in Asia-Pacific, 2021-2030 (USD Million)
Table 18.136 Gene Therapy CROs Market for Oncological Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 18.137 Gene Therapy CROs Market for Cardiovascular Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 18.138 Gene Therapy CROs Market for Inflammatory Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 18.139 Gene Therapy CROs Market for Neurological Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 18.140 Gene Therapy CROs Market for Other Therapeutic Areas in Asia-Pacific, 2021-2030 (USD Million)
Table 18.141 Gene Therapy CROs Market for Clinical Operations in Asia-Pacific, 2021-2030 (USD Million)
Table 18.142 Gene Therapy CROs Market for Preclinical Operations in Asia-Pacific, 2021-2030 (USD Million)
Table 18.143 Gene Therapy CROs Market in Latin America, 2021-2030 (USD Million)
Table 18.144 Gene Therapy CROs Market in Middle East North America, 2021-2030 (USD Million)
Table 18.145 Gene Therapy CROs Market: Conservative, Base and Optimistic Scenarios, 2020, 2025 and 2030 (USD Million)
The following companies / institutes / government bodies and organizations have been mentioned in this report.
Discounts available for multiple report purchases
sales@rootsanalysis.com